[144] Madrigal Pharmaceuticals, Inc. SEC Filing
Madrigal Pharmaceuticals (MDGL) filed a Form 144 reporting a proposed sale of 43,263 common shares through Morgan Stanley Smith Barney, with an aggregate market value of $15,120,418.50 and 22,289,014 shares outstanding. The filing states the shares were acquired and are to be sold on 08/12/2025 following an exercise of stock options, with payment in cash. The notice also lists multiple recent 10b5-1 insider sales by Rebecca Taub and Paul A. Friedman in July鈥揂ugust 2025, including large transactions on 07/16/2025. Several identifying fields for the filer/issuer in the provided form appear blank.
Madrigal Pharmaceuticals (MDGL) ha presentato un Form 144 segnalando la proposta di vendita di 43,263 azioni ordinarie tramite Morgan Stanley Smith Barney, con un valore di mercato complessivo di $15,120,418.50 e 22,289,014 azioni in circolazione. Il deposito indica che le azioni sono state acquisite e saranno vendute il 08/12/2025 a seguito dell'esercizio di opzioni su azioni, con pagamento in contanti. L'avviso elenca inoltre diverse vendite di insider ai sensi della regola 10b5-1 effettuate di recente da Rebecca Taub e Paul A. Friedman tra luglio e agosto 2025, incluse transazioni rilevanti il 07/16/2025. Diversi campi identificativi del dichiarante/emittente nel modulo fornito risultano vuoti.
Madrigal Pharmaceuticals (MDGL) present贸 un Form 144 informando una propuesta de venta de 43,263 acciones ordinarias a trav茅s de Morgan Stanley Smith Barney, con un valor de mercado agregado de $15,120,418.50 y 22,289,014 acciones en circulaci贸n. El documento indica que las acciones fueron adquiridas y se vender谩n el 08/12/2025 tras el ejercicio de opciones sobre acciones, con pago en efectivo. La notificaci贸n tambi茅n enumera varias ventas recientes de insiders bajo 10b5-1 realizadas por Rebecca Taub y Paul A. Friedman en julio鈥揳gosto de 2025, incluidas operaciones de gran volumen el 07/16/2025. Varios campos identificativos del declarante/emisor en el formulario proporcionado aparecen en blanco.
Madrigal Pharmaceuticals (MDGL)臧� 鞝滌晥霅� 43,263 氤错喌欤� 毵り皝鞚� 氤搓碃頃橂姅 Form 144毳� Morgan Stanley Smith Barney毳� 韱淀暣 鞝滌稖頄堨溂氅�, 齑� 鞁滉皜 $15,120,418.50 氚� 22,289,014欤检潣 氚滍枆欤检嫕靾橂ゼ 旮半頄堨姷雼堧嫟. 鞝滌稖靹滌棎 霐半ゴ氅� 頃措嫻 欤检嫕鞚� 旆摑霅橃棃瓿� 08/12/2025鞐� 鞀ろ啞鞓奠厴 頄夓偓鞐� 霐半澕 順勱笀鞙茧 毵り皝霅� 鞓堨爼鞛呺媹雼�. 韱奠靹滌棎電� 霕愴暅 Rebecca Taub鞕� Paul A. Friedman鞚� 2025雲� 7鞗攡8鞗旍棎 靾橅枆頃� 鞐煬 瓯挫潣 10b5-1 雮措秬鞛� 毵る弰臧� 旮办灛霅橃柎 鞛堨溂氅�, 07/16/2025鞚� 雽�攴滊 瓯半灅霃� 韽暔霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖霅� 鞏戩嫕鞚� 鞐煬 鞁濍硠 頃鞚� 牍勳柎 鞛堧姅 瓴冹溂搿� 氤挫瀰雼堧嫟.
Madrigal Pharmaceuticals (MDGL) a d茅pos茅 un Form 144 signalant une proposition de vente de 43,263 actions ordinaires via Morgan Stanley Smith Barney, avec une valeur de march茅 agr茅g茅e de $15,120,418.50 et 22,289,014 actions en circulation. Le dossier indique que les actions ont 茅t茅 acquises et seront vendues le 08/12/2025 脿 la suite de l'exercice d'options sur actions, avec paiement en esp猫ces. L'avis 茅num猫re 茅galement plusieurs ventes r茅centes d'initi茅s au titre du 10b5-1 par Rebecca Taub et Paul A. Friedman en juillet鈥揳o没t 2025, y compris des op茅rations importantes le 07/16/2025. Plusieurs champs d'identification du d茅clarant/茅metteur dans le formulaire fourni semblent vides.
Madrigal Pharmaceuticals (MDGL) hat ein Form 144 eingereicht, in dem ein geplanter Verkauf von 43,263 Stammaktien 眉ber Morgan Stanley Smith Barney gemeldet wird, mit einem aggregierten Marktwert von $15,120,418.50 und 22,289,014 ausstehenden Aktien. Die Einreichung gibt an, dass die Aktien erworben wurden und am 08/12/2025 nach einer Aus眉bung von Aktienoptionen gegen Barzahlung verkauft werden sollen. Die Mitteilung listet au脽erdem mehrere j眉ngste 10b5-1-Insiderverk盲ufe von Rebecca Taub und Paul A. Friedman im Juli鈥揂ugust 2025 auf, darunter gr枚脽ere Transaktionen am 07/16/2025. Mehrere Identifikationsfelder f眉r den Einreicher/Emittenten im vorgelegten Formular sind leer.
- Form 144 filed providing public disclosure of the proposed sale of 43,263 shares
- Broker identified as Morgan Stanley Smith Barney LLC, giving execution routing details
- Securities were acquired by exercise of stock options and payment was in cash on the stated date
- Multiple sizeable 10b5-1 insider sales in the past three months, including Rebecca Taub: 26,444 shares for $9,347,062.51 on 07/16/2025
- Multiple sizeable 10b5-1 insider sales in the past three months, including Paul A. Friedman: 26,176 shares for $9,252,542.95 on 07/16/2025
- Several filer/issuer identifying fields in the provided form appear blank, limiting immediate verification from this document alone
Insights
TL;DR: Multiple scheduled insider sales disclosed; Form 144 shows a proposed sale of 43,263 shares valued at $15.12M.
The filing documents a straightforward Form 144 notice for the proposed public sale of 43,263 common shares via Morgan Stanley Smith Barney with a stated market value of $15,120,418.50. The shares were acquired and are to be sold on 08/12/2025 via exercise of stock options and paid in cash. The form also enumerates several 10b5-1 plan sales by named insiders in July鈥揂ugust 2025, producing multi-million dollar gross proceeds. This is disclosure of insider liquidity rather than an operational update.
TL;DR: Disclosure includes multiple insider 10b5-1 sales and required certifications, though some filer/issuer fields are blank.
The notice includes the statutory signature and representation language and identifies the broker and transaction details. It documents acquisition by option exercise and lists recent 10b5-1 sales by Rebecca Taub and Paul A. Friedman with exact dates and proceeds. The form as provided omits certain filer/issuer identification entries, which should be complete for full transparency in public filings.
Madrigal Pharmaceuticals (MDGL) ha presentato un Form 144 segnalando la proposta di vendita di 43,263 azioni ordinarie tramite Morgan Stanley Smith Barney, con un valore di mercato complessivo di $15,120,418.50 e 22,289,014 azioni in circolazione. Il deposito indica che le azioni sono state acquisite e saranno vendute il 08/12/2025 a seguito dell'esercizio di opzioni su azioni, con pagamento in contanti. L'avviso elenca inoltre diverse vendite di insider ai sensi della regola 10b5-1 effettuate di recente da Rebecca Taub e Paul A. Friedman tra luglio e agosto 2025, incluse transazioni rilevanti il 07/16/2025. Diversi campi identificativi del dichiarante/emittente nel modulo fornito risultano vuoti.
Madrigal Pharmaceuticals (MDGL) present贸 un Form 144 informando una propuesta de venta de 43,263 acciones ordinarias a trav茅s de Morgan Stanley Smith Barney, con un valor de mercado agregado de $15,120,418.50 y 22,289,014 acciones en circulaci贸n. El documento indica que las acciones fueron adquiridas y se vender谩n el 08/12/2025 tras el ejercicio de opciones sobre acciones, con pago en efectivo. La notificaci贸n tambi茅n enumera varias ventas recientes de insiders bajo 10b5-1 realizadas por Rebecca Taub y Paul A. Friedman en julio鈥揳gosto de 2025, incluidas operaciones de gran volumen el 07/16/2025. Varios campos identificativos del declarante/emisor en el formulario proporcionado aparecen en blanco.
Madrigal Pharmaceuticals (MDGL)臧� 鞝滌晥霅� 43,263 氤错喌欤� 毵り皝鞚� 氤搓碃頃橂姅 Form 144毳� Morgan Stanley Smith Barney毳� 韱淀暣 鞝滌稖頄堨溂氅�, 齑� 鞁滉皜 $15,120,418.50 氚� 22,289,014欤检潣 氚滍枆欤检嫕靾橂ゼ 旮半頄堨姷雼堧嫟. 鞝滌稖靹滌棎 霐半ゴ氅� 頃措嫻 欤检嫕鞚� 旆摑霅橃棃瓿� 08/12/2025鞐� 鞀ろ啞鞓奠厴 頄夓偓鞐� 霐半澕 順勱笀鞙茧 毵り皝霅� 鞓堨爼鞛呺媹雼�. 韱奠靹滌棎電� 霕愴暅 Rebecca Taub鞕� Paul A. Friedman鞚� 2025雲� 7鞗攡8鞗旍棎 靾橅枆頃� 鞐煬 瓯挫潣 10b5-1 雮措秬鞛� 毵る弰臧� 旮办灛霅橃柎 鞛堨溂氅�, 07/16/2025鞚� 雽�攴滊 瓯半灅霃� 韽暔霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖霅� 鞏戩嫕鞚� 鞐煬 鞁濍硠 頃鞚� 牍勳柎 鞛堧姅 瓴冹溂搿� 氤挫瀰雼堧嫟.
Madrigal Pharmaceuticals (MDGL) a d茅pos茅 un Form 144 signalant une proposition de vente de 43,263 actions ordinaires via Morgan Stanley Smith Barney, avec une valeur de march茅 agr茅g茅e de $15,120,418.50 et 22,289,014 actions en circulation. Le dossier indique que les actions ont 茅t茅 acquises et seront vendues le 08/12/2025 脿 la suite de l'exercice d'options sur actions, avec paiement en esp猫ces. L'avis 茅num猫re 茅galement plusieurs ventes r茅centes d'initi茅s au titre du 10b5-1 par Rebecca Taub et Paul A. Friedman en juillet鈥揳o没t 2025, y compris des op茅rations importantes le 07/16/2025. Plusieurs champs d'identification du d茅clarant/茅metteur dans le formulaire fourni semblent vides.
Madrigal Pharmaceuticals (MDGL) hat ein Form 144 eingereicht, in dem ein geplanter Verkauf von 43,263 Stammaktien 眉ber Morgan Stanley Smith Barney gemeldet wird, mit einem aggregierten Marktwert von $15,120,418.50 und 22,289,014 ausstehenden Aktien. Die Einreichung gibt an, dass die Aktien erworben wurden und am 08/12/2025 nach einer Aus眉bung von Aktienoptionen gegen Barzahlung verkauft werden sollen. Die Mitteilung listet au脽erdem mehrere j眉ngste 10b5-1-Insiderverk盲ufe von Rebecca Taub und Paul A. Friedman im Juli鈥揂ugust 2025 auf, darunter gr枚脽ere Transaktionen am 07/16/2025. Mehrere Identifikationsfelder f眉r den Einreicher/Emittenten im vorgelegten Formular sind leer.
FAQ
What did Madrigal (MDGL) report on this Form 144?
Who is the broker handling the proposed sale?
How were the securities acquired?
Have insiders sold shares recently under 10b5-1 plans?
Are there any missing details in the provided filing?
